Two Sigma Advisers
CYTK icon

Two Sigma Advisers’s Cytokinetics CYTK Stock Holding History

Two Sigma Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-174,700
Closed -$11.1M – 560
2025
Q4 		$11.1M Buy
+174,700
New +$10.9M 0.02% 503
2025
Q2 		– Sell
-80,400
Closed -$3.23M – 2363
2025
Q1 		$3.23M Sell
80,400
-146,000
-64% -$6.71M 0.01% 962
2024
Q4 		$10.6M Buy
226,400
+11,700
+5% +$608K 0.02% 466
2024
Q3 		$11.3M Buy
+214,700
New +$12M 0.03% 459
2024
Q2 		– Sell
-7,000
Closed -$491K – 2493
2024
Q1 		$491K Sell
7,000
-76,800
-92% -$5.94M ﹤0.01% 1878
2023
Q4 		$7M Sell
83,800
-93,100
-53% -$3.37M 0.02% 670
2023
Q3 		$5.21M Sell
176,900
-101,500
-36% -$3.38M 0.01% 711
2023
Q2 		$9.08M Sell
278,400
-178,600
-39% -$6.61M 0.02% 525
2023
Q1 		$16.1M Buy
457,000
+2,000
+0.4% +$81.6K 0.04% 395
2022
Q4 		$20.8M Buy
455,000
+53,100
+13% +$2.28M 0.06% 327
2022
Q3 		$19.5M Sell
401,900
-62,500
-13% -$3.01M 0.06% 333
2022
Q2 		$18.2M Sell
464,400
-114,900
-20% -$4.63M 0.05% 343
2022
Q1 		$21.3M Sell
579,300
-199,800
-26% -$7.1M 0.06% 314
2021
Q4 		$35.5M Sell
779,100
-40,800
-5% -$1.57M 0.09% 196
2021
Q3 		$29.3M Sell
819,900
-57,100
-7% -$1.68M 0.08% 237
2021
Q2 		$17.4M Sell
877,000
-98,300
-10% -$2.31M 0.05% 370
2021
Q1 		$22.7M Buy
975,300
+221,200
+29% +$4.72M 0.06% 333
2020
Q4 		$15.7M Sell
754,100
-43,400
-5% -$793K 0.04% 413
2020
Q3 		$17.3M Buy
797,500
+70,300
+10% +$1.64M 0.05% 360
2020
Q2 		$17.1M Buy
727,200
+53,400
+8% +$1M 0.05% 368
2020
Q1 		$7.94M Buy
673,800
+153,000
+29% +$1.95M 0.03% 563
2019
Q4 		$5.53M Buy
520,800
+250,000
+92% +$2.57M 0.01% 808
2019
Q3 		$3.08M Buy
270,800
+14,300
+6% +$179K 0.01% 942
2019
Q2 		$2.89M Buy
256,500
+24,100
+10% +$232K 0.01% 1045
2019
Q1 		$1.88M Buy
232,400
+168,700
+265% +$1.24M ﹤0.01% 1248
2018
Q4 		$403K Sell
63,700
-3,200
-5% -$23.5K ﹤0.01% 1857
2018
Q3 		$659K Sell
66,900
-11,700
-15% -$93.9K ﹤0.01% 1687
2018
Q2 		$652K Sell
78,600
-5,400
-6% -$44.9K ﹤0.01% 1807
2018
Q1 		$605K Buy
84,000
+9,200
+12% +$78.9K ﹤0.01% 1752
2017
Q4 		$610K Buy
74,800
+28,800
+63% +$327K ﹤0.01% 1713
2017
Q3 		$667K Buy
46,000
+8,300
+22% +$113K ﹤0.01% 1637
2017
Q2 		$456K Sell
37,700
-2,800
-7% -$38.9K ﹤0.01% 1825
2017
Q1 		$520K Sell
40,500
-8,900
-18% -$104K ﹤0.01% 1879
2016
Q4 		$600K Sell
49,400
-40,300
-45% -$428K ﹤0.01% 1773
2016
Q3 		$823K Buy
89,700
+45,800
+104% +$478K ﹤0.01% 1453
2016
Q2 		$417K Sell
43,900
-23,300
-35% -$191K ﹤0.01% 1593
2016
Q1 		$474K Sell
67,200
-11,395
-14% -$83.2K ﹤0.01% 1482
2015
Q4 		$822K Buy
78,595
+66,493
+549% +$652K ﹤0.01% 1112
2015
Q3 		$81K Buy
+12,102
New +$82.6K ﹤0.01% 1733

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers's CYTK Position: Q1 2026 in Review

Two Sigma Advisers sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 174,700 shares — an estimated $11.1M sold.

Two Sigma Advisers first reported a position in CYTK in Q3 2015 and held it in 39 quarters. The position peaked at $35.5M in Q4 2021. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Two Sigma Advisers reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 174,700 Cytokinetics shares in Q1 2026, an estimated $11.1M.
  • Two Sigma Advisers first reported a position in Cytokinetics in Q3 2015 and held it in 39 quarters.
  • Two Sigma Advisers's Cytokinetics position peaked at $35.5M in Q4 2021.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.